Zomedica Corp (AMEX: ZOM) stock jumped 2.26% on Friday to $0.17 against a previous-day closing price of $0.16. With 2.85 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.42 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.1685 whereas the lowest price it dropped to was $0.1630. The 52-week range on ZOM shows that it touched its highest point at $0.34 and its lowest point at $0.15 during that stretch. It currently has a 1-year price target of $0.44. Beta for the stock currently stands at 0.94.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZOM was down-trending over the past week, with a drop of -7.17%, but this was down by -1.71% over a month. Three-month performance dropped to -11.82% while six-month performance fell -18.49%. The stock lost -24.70% in the past year, while it has gained 2.52% so far this year. A look at the trailing 12-month EPS for ZOM yields -0.02 with Next year EPS estimates of -0.01. For the next quarter, that number is 0.00. This implies an EPS growth rate of 50.00% for this year and 0.00% for next year.
Float and Shares Shorts:
At present, 979.95 million ZOM shares are outstanding with a float of 964.81 million shares on hand for trading. On Oct 30, 2023, short shares totaled 62.89 million, which was 6.42% higher than short shares on Sep 28, 2023. In addition to Mr. Larry C. Heaton II as the firm’s President, CEO & Director, Mr. Adrian Lock serves as its VP, GM & Head of Sales.
Other institutions hold 6.22% of ZOM, in contrast to 2.33% held by mutual funds. Shares owned by individuals account for 1.71%. As the largest shareholder in ZOM with 4.94% of the stake, The Vanguard Group, Inc. holds 48,437,481 shares worth 48,437,481. A second-largest stockholder of ZOM, BlackRock Fund Advisors, holds 10,390,650 shares, controlling over 1.06% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in ZOM, holding 9,640,982 shares or 0.98% stake. With a 3.44% stake in ZOM, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 33,687,896 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.36% of ZOM stock, is the second-largest Mutual Fund holder. It holds 13,318,083 shares valued at 2.24 million. Fidelity Extended Market Index Fu holds 0.52% of the stake in ZOM, owning 5,134,462 shares worth 0.86 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZOM since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ZOM analysts setting a high price target of $0.44 and a low target of $0.44, the average target price over the next 12 months is $0.44. Based on these targets, ZOM could surge 158.82% to reach the target high and rise by 158.82% to reach the target low. Reaching the average price target will result in a growth of 158.82% from current levels.
Summary of Insider Activity:
Insiders traded ZOM stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 4 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 400,000 while 0 shares were sold.